Results 201 to 210 of about 2,436,024 (405)

Model for bridging the gap: establishing an oncology primary care clinic for comprehensive survivorship care. [PDF]

Fam Med Community Health
Topalian AG, Erickson M, Brewer T, Kushman S, Shaughnessy E, Butsch Kovacic M.   +5 more
europepmc   +1 more source

Oncology update

Middle East African Journal of Ophthalmology, 2010
openaire   +3 more sources

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Journal of Clinical Oncology, 2010
P. Wen, D. R. MacDonald, D. Reardon, T. Cloughesy, A. Sorensen, E. Galanis, J. Degroot, W. Wick, M. Gilbert, A. Lassman, C. Tsien, T. Mikkelsen, Eric T. Wong, M. Chamberlain, R. Stupp, K. Lamborn, M. Vogelbaum, M. J. van den Bent, Susan M. Chang   +18 more
semanticscholar   +1 more source

Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

Nature Cancer, 2020
S. M. Corsello, Rohith T. Nagari, R. Spangler, J. Rossen, M. Kocak, Jordan G. Bryan, Ranad Humeidi, David Peck, Xiaoyun Wu, A. Tang, Vickie M. Wang, Samantha A Bender, E. Lemire, Rajiv Narayan, Philip Montgomery, U. Ben-David, C. Garvie, Yejia Chen, M. Rees, Nicholas J. Lyons, James M. McFarland, Bang Wong, Li R. Wang, N. Dumont, Patrick J O'Hearn, Eric Stefan, John G Doench, C. Harrington, H. Greulich, M. Meyerson, F. Vazquez, A. Subramanian, J. Roth, Joshua A. Bittker, J. Boehm, C. Mader, Aviad Tsherniak, T. Golub   +37 more
semanticscholar   +1 more source

Radiotheranostics in oncology: current challenges and emerging opportunities

Nature Reviews Clinical Oncology, 2022
L. Bodei, K. Herrmann, H. Schöder, A. Scott, Jason S. Lewis   +4 more
semanticscholar   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Correction: Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer. [PDF]

Sci Rep
Ren W, Liu J, Zhao R, Zhao F, Zhang Y, Mu J, Zhu T.   +6 more
europepmc   +1 more source

Oncology Institute of Guatemala: Experience With NK/T-Cell Lymphomas

, 2016
Fabiola Valvert, D. Flores
openalex   +1 more source

Primary Extra-Gastrointestinal Stromal Tumors (E-GIST) of the Liver, about Two Cases and Review of the Literature Oncology Hospital Experience at Chu Hassan II in FES

, 2023
Oumaima Siyouri, Mohammed Ismaili, Khaoula Alaoui Ismaili, Imane Stitou, Hajar Medyouni, Jihane Chouef, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas   +10 more
openalex   +2 more sources

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source